Global Retirement Partners LLC raised its stake in Abbott Laboratories (NYSE:ABT – Free Report) by 14.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 51,718 shares of the healthcare product maker’s stock after acquiring an additional 6,570 shares during the quarter. Global Retirement Partners LLC’s holdings in Abbott Laboratories were worth $5,111,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ABT. Foresight Capital Management Advisors Inc. acquired a new stake in shares of Abbott Laboratories in the third quarter valued at approximately $31,000. Manning & Napier Advisors LLC bought a new position in Abbott Laboratories in the 2nd quarter worth approximately $31,000. Balance Wealth Partners LLC acquired a new position in Abbott Laboratories during the 3rd quarter worth $34,000. Summit Securities Group LLC lifted its holdings in Abbott Laboratories by 41.3% during the 2nd quarter. Summit Securities Group LLC now owns 404 shares of the healthcare product maker’s stock worth $37,000 after buying an additional 118 shares in the last quarter. Finally, Addison Advisors LLC bought a new position in Abbott Laboratories in the 2nd quarter valued at $40,000. Institutional investors and hedge funds own 75.18% of the company’s stock.
Abbott Laboratories Stock Performance
ABT stock opened at $104.48 on Thursday. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $131.49. The company has a quick ratio of 1.00, a current ratio of 1.45 and a debt-to-equity ratio of 0.57. The company has a market cap of $180.96 billion, a P/E ratio of 38.99, a price-to-earnings-growth ratio of 1.84 and a beta of 0.54. The business’s fifty day moving average is $103.88 and its 200-day moving average is $101.71.
Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, hitting analysts’ consensus estimates of $1.42. Abbott Laboratories had a return on equity of 18.04% and a net margin of 9.75%. The business had revenue of $13.01 billion during the quarter, compared to analysts’ expectations of $12.99 billion. The firm’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.30 earnings per share. Equities research analysts forecast that Abbott Laboratories will post 5.52 EPS for the current year.
Abbott Laboratories Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Monday, November 16th. Shareholders of record on Thursday, October 15th were issued a dividend of $0.63 per share. The ex-dividend date was Thursday, October 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. Abbott Laboratories’s dividend payout ratio (DPR) is 94.03%.
Analysts Set New Price Targets
ABT has been the subject of several research reports. Rothschild & Co Redburn raised Abbott Laboratories from a “neutral” rating to a “buy” rating and lifted their target price for the company from $119.00 to $127.00 in a research note on Friday, October 2nd. JPMorgan Chase & Co. cut their price target on Abbott Laboratories from $120.00 to $118.00 and set an “overweight” rating on the stock in a research note on Thursday, October 22nd. Barclays began coverage on Abbott Laboratories in a report on Wednesday, October 7th. They issued an “overweight” rating and a $120.00 price target on the stock. UBS Group decreased their price target on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a report on Tuesday, July 28th. Finally, Wall Street Zen upgraded Abbott Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, October 24th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $118.32.
Get Our Latest Analysis on ABT
Insider Transactions at Abbott Laboratories
In other news, EVP Mary Moreland sold 3,500 shares of the business’s stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $116.00, for a total transaction of $406,000.00. Following the completion of the transaction, the executive vice president directly owned 100,791 shares in the company, valued at approximately $11,691,756. The trade was a 3.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.46% of the company’s stock.
Abbott Laboratories Company Profile
Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.
See Also
- Five stocks we like better than Abbott Laboratories
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
